Free Trial
NASDAQ:KRON

Kronos Bio (KRON) Stock Price, News & Analysis

Kronos Bio logo
$1.00 +0.03 (+3.08%)
As of 01/3/2025 05:22 PM Eastern

About Kronos Bio Stock (NASDAQ:KRON)

Key Stats

Today's Range
$0.95
$1.01
50-Day Range
$0.83
$1.07
52-Week Range
$0.69
$1.60
Volume
202,563 shs
Average Volume
116,582 shs
Market Capitalization
$60.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.63
Consensus Rating
Hold

Company Overview

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
58th Percentile Overall Score

KRON MarketRank™: 

Kronos Bio scored higher than 58% of companies evaluated by MarketBeat, and ranked 489th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kronos Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kronos Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Kronos Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Kronos Bio are expected to grow in the coming year, from ($1.33) to ($1.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kronos Bio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kronos Bio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kronos Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.28% of the float of Kronos Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Kronos Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kronos Bio has recently decreased by 1.06%, indicating that investor sentiment is improving.
  • Dividend Yield

    Kronos Bio does not currently pay a dividend.

  • Dividend Growth

    Kronos Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.28% of the float of Kronos Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Kronos Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kronos Bio has recently decreased by 1.06%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Kronos Bio this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Kronos Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kronos Bio's insider trading history.
Receive KRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

KRON Stock News Headlines

Kronos Bio Inc Ordinary Shares
The Tiny Device Behind Elon’s Next Big Thing
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Kronos Bio announces workforce reduction of 83% by year-end
Kronos Bio to lay off 83% of staff as CEO steps down
See More Headlines

KRON Stock Analysis - Frequently Asked Questions

Kronos Bio's stock was trading at $0.95 at the beginning of 2025. Since then, KRON stock has increased by 5.3% and is now trading at $1.00.
View the best growth stocks for 2025 here
.

Kronos Bio, Inc. (NASDAQ:KRON) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $2.69 million for the quarter, compared to analysts' expectations of $1.75 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.55% and a negative net margin of 867.66%.

Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD).

Company Calendar

Last Earnings
8/08/2024
Today
1/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KRON
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.63
High Stock Price Target
$2.25
Low Stock Price Target
$1.00
Potential Upside/Downside
+62.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-112,670,000.00
Net Margins
-867.66%
Pretax Margin
-867.66%

Debt

Sales & Book Value

Annual Sales
$9.86 million
Book Value
$2.73 per share

Miscellaneous

Free Float
45,618,000
Market Cap
$60.34 million
Optionable
Optionable
Beta
1.83
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:KRON) was last updated on 1/6/2025 by MarketBeat.com Staff
From Our Partners